Shared on08 Aug 25Fair value Decreased 15%
The decrease in GoodRx Holdings' consensus price target is primarily driven by a notable decline in future P/E multiples and an increased discount rate, resulting in a revised fair value of $5.91. What's in the News GoodRx issued 2025 revenue guidance, expecting an increase over 2024’s $792.3 million.